Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722717 | 0.78 | NISCH (0.38) | NISCHNPC1RAB9AKDM4ETP53 | |
| SCHEMBL16418615 | 0.75 | — | — | |
| SCHEMBL135687 | 0.75 | KIF11 (0.32) | KIF11 | |
| SCHEMBL14008987 | 0.73 | KIF11 (0.44) | KIF11HTR1DADRA1ANISCHNPC1 | |
| SCHEMBL26915 | 0.68 | KIF11 (0.70) | KIF11HTR1DADRA1ANISCHNPC1 | |
| SCHEMBL3423876 | 0.68 | KIF11 (0.70) | KIF11HTR1DADRA1ANISCHNPC1 | |
| Lithium SCHEMBL29536927 | 0.66 | KIF11 (0.67) | KIF11HTR1DADRA1ANISCHNPC1 | |
| Lithium SCHEMBL30081449 | 0.66 | KIF11 (0.67) | KIF11HTR1DADRA1ANISCHNPC1 | |
| SCHEMBL1931781 | 0.66 | KIF11 (0.67) | KIF11HTR1DADRA1ANISCHNPC1 | |
| SCHEMBL3999289 | 0.66 | KIF11 (1.00) | KIF11HTR1DADRA1ANISCHNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185361-A1 | METHODS FOR TREATING CANCER USING DIHYDROPYRAZINO-PYRAZINE COMPOUND COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2018-07-05 | — | — | US | disclosed |
| US-10004735-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-9980963-B2 | Treatment of cancer with dihydropyrazino-pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9937170-B2 | Treatment of cancer with TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170342080-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170312278-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY COMPRISING ADMINISTERING SUBSTITUTED PYRAZINO[2,3-b]PYRAZINES | SIGNAL PHARM LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-9782427-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-9737535-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170182044-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | SIGNAL PHARM LLC (US) | 2017-06-29 | — | — | US | disclosed |
| US-9630966-B2 | Treatment of cancer with dihydropyrazino-pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-20130245028-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245029-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245027-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130225518-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8507492-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130158023-A1 | IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20120059164-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | PERRIN-NINKOVIC SOPHIE (US) | 2012-03-08 | — | — | US | disclosed |
| US-8110578-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-20 | — | — | US | disclosed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245027-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, BRCA1 | KIF11 1800/4885HTR1D 4502/4885ADRA1A 4268/4885 |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | STK11, STK16, STK10 | KIF11 1610/4885HTR1D 4865/4885ADRA1A 4642/4885 |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | KIF11 4707/4885HTR1D 2991/4885ADRA1A 3935/4885 |
| US-20170182044-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | MGMT, DNMT1, TPMT | KIF11 2380/4885HTR1D 4556/4885ADRA1A 4641/4885 |
| US-20130225518-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | DCK, DTYMK, MTOR | KIF11 2418/4885HTR1D 4680/4885ADRA1A 4544/4885 |
| US-20130158023-A1 | IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | STK16, STK10, STK11 | KIF11 1051/4885HTR1D 4864/4885ADRA1A 4806/4885 |
| US-20130245029-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | EWSR1, ELF3, MTOR | KIF11 2048/4885HTR1D 4666/4885ADRA1A 4518/4885 |
| US-10004735-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | MTOR, ULK2, TTK | KIF11 1459/4885HTR1D 4688/4885ADRA1A 4620/4885 |
| US-20130245028-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | ELF3, ERG, MTOR | KIF11 2363/4885HTR1D 4752/4885ADRA1A 4100/4885 |
| US-20180185361-A1 | METHODS FOR TREATING CANCER USING DIHYDROPYRAZINO-PYRAZINE COMPOUND COMBINATION THERAPY | AR, NR5A2, GNRHR | KIF11 935/4885HTR1D 2872/4885ADRA1A 741/4885 |
| US-20170342080-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | KIF11 4674/4885HTR1D 2967/4885ADRA1A 3733/4885 |
| US-20170312278-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY COMPRISING ADMINISTERING SUBSTITUTED PYRAZINO[2,3-b]PYRAZINES | MTOR, ULK2, TTK | KIF11 1459/4885HTR1D 4688/4885ADRA1A 4620/4885 |
| US-20120059164-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | KIF11 4676/4885HTR1D 2970/4885ADRA1A 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.